Search

HARMONY: Innovative Medicines Initiative approves € 40 million project for better care of patients with hematologic malignancies

Feb 01 2017

HARMONY will capture, integrate, analyze and harmonize anonymous patient data from high-quality multidisciplinary sources to unlock valuable knowledge on multiple myeloma (MM), acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), non-Hodgkins lymphoma (NHL), myelodysplastic syndromes (MDS)…

EHA’s advocacy for hematology continues

Oct 25 2016

The EHA Board has recently approved five position papers which formulate EHA’s key lobbying priorities:

Support for hematology research in Horizon 2020 (and future EU research funding programs)
Access to treatment for patients with blood disorders
EU collaboration to reduce the prices…

Young researchers to benefit from EHA training and mentoring

Oct 24 2016

Participation in EHA-CRTH will allow these researchers to fine-tune the skills and knowledge required to successfully design, run and complete clinical trials.

Improved survival for adult Acute Lymphoblastic Leukemia (ALL) patients

Jun 11 2016 Posted in Press releases

Historical survival for patients 18-45 years with ALL is approximately 40 %. However the event free survival for ALL patients 18-45 years has improved to 73% following implementation of the NOPHO ALL2008 protocol in July 2008.

The Clot Thickens

Jun 11 2016 Posted in Press releases

Haemophilia B is a genetic bleeding disorder, affecting approximately 80,000 males worldwide1, caused by an insufficient or dyfunctional blood clotting protein called factor IX (FIX).

EHA Award winners put in the spotlight in Copenhagen

Jun 10 2016 Posted in Press releases

The EHA-José Carreras Non-Clinical Junior Fellowship is made possible with the support of the German José Carreras Foundation.

A new targeted combination therapy with potential to eliminate relapsed chronic lymphocytic leukemia

Jun 12 2015 Posted in Press releases

Patients with chronic lymphocytic leukemia (CLL) that has recurred or isn’t responding to standard treatment need new therapies. A new combination of two targeted therapies is showing potential to eliminate CLL in these circumstances.

Adding elotuzumab to standard treatment for multiple myeloma significantly reduced the risk of disease progression, with benefits sustained at two years

Jun 12 2015

ELOQUENT-2, which evaluated elotuzumab in combination with lenalidomide and dexamethasone, is the first Phase III study to demonstrate the benefit of directly activating the immune system in the treatment of patients with relapsed or refractory multiple myeloma.

Jesus San Miguel presents the Ham-Wasserman Lecture at the 2014 ASH Annual Meeting

Dec 06 2014 Posted in Press releases

Professor San Miguel is a member of the Advisory board of the International Myeloma Foundation and the Multiple Myeloma Research Foundation.

Announcement: The award winners of the prestigious EHA-ASH Translational Research in Hematology Training Award are selected

Nov 25 2014 Posted in Press releases

The winners of the TRTH 2015 Awards are:

Name

Nationality

Name

Nationality

Ileana Antony-Debre

French

Jean-Baptiste Micol

French

Pavan Bachireddy

American

Christopher Ott

American

Lucile Couronné

French

Carsten Riether

German

Moniek de Witte

Dutch

Anindita Roy

British

Ammon Fager

American

Melody Smith

American

Gillian Horne

British

Zuzana Tothova

Slovakian

Moonjung Jung

South Korea

Marcin Wlodarski

Polish

Jonas Samuel Jutzi

Swiss - German

Yuh-Ying Yeh

Taiwanese

Milka Koupenova-Zamor

American - Bulgarian

Sasan Zandi

Iranian

Marwan Kwok

British

Patricia Maiso

Spain

Are you interested in joining the…